Background. Between August 1984 and November 1989, the Hoosier Oncology Group conducted a Phase III study comparing cyclophosphamide (CTX) with cyclophosphamide, doxorubicin, and methotrexate (CAM) in patients with hormone‐refractory metastatic prostatic cancer to determine whether the addition of doxorubicin and methotrexate to the cyclophosphamide regimen conferred any survival advantage. Methods. One hundred three patients were registered and randomized, 99 were evaluable for response, and all were evaluable for survival results. All had histologically confirmed metastatic prostatic cancer and had not responded to hormonal therapy. Fifty‐three patients received CTX alone, and 50 received CAM. Seventy‐one patients (69%) had evaluable disease, and 32 (31%) had measurable disease. Results. There were no complete responses and only four (13%) partial responses in the patients with measurable disease. There was no difference in overall survival time between the two treatment arms in either patients with a Karnofsky performance status (KPS) of 80‐100 (median survival, 9.0 versus 9.5 months; P = 0.93) or in those with a KPS of 50‐70 (median survival, 5.0 versus 6.0 months; P = 0.51). There was no difference in overall time to progression between the two treatment arms (median time to progression; 4.4 versus 6.2 months; P = 0.07). Toxicity was tolerable in both regimens. Conclusions. It was concluded that there was no survival advantage to CAM over CTX alone. New chemo‐therapeutic agents with greater activity against prostatic cancer must be identified.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Nov 15 1992|
ASJC Scopus subject areas
- Cancer Research